Testosterone gel indicated for treatment of hypogonadism.

Auxilium Pharmaceuticals and Ferring International inked an exclusive agreement for the European distribution and license rights to Testim, a topical 1% testosterone once-a-day gel indicated for the treatment of hypogonadism.

Under the agreement, Auxilium will be responsible for manufacturing and supplying Testim to Ferring, while Ferring will be responsible for all regulatory, sales, marketing, and distribution activities in Europe. In addition, Auxilium will receive a combination of upfront, milestone, and royalty payments.

“We are very pleased to have Ferring as our partner, given the strength of their European specialty urology and endocrinology franchises, their existing commercial infrastructure across Europe, and the successful track record they have established in commercializing differentiated products in the EU,” said Armando Anido, CEO and president of Auxilium. “This agreement enables us to bring our testosterone replacement product to patients in all of the 15 countries where Testim has been approved and potentially in additional new countries within Europe, thus expanding the reach of our Testim franchise outside the U.S.”

Previous articleTigermed Sets Up Subsidiary
Next articleNew Receptor Sites Key to Helping Exhausted T Cells Fight Cancer